Suppr超能文献

弥漫性内生脑桥胶质瘤免疫微环境的特征:对免疫治疗发展的影响。

Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.

机构信息

Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington.

Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.

出版信息

Neuro Oncol. 2019 Jan 1;21(1):83-94. doi: 10.1093/neuonc/noy145.

Abstract

BACKGROUND

Diffuse intrinsic pontine glioma (DIPG) is a uniformly fatal CNS tumor diagnosed in 300 American children per year. Radiation is the only effective treatment and extends overall survival to a median of 11 months. Due to its location in the brainstem, DIPG cannot be surgically resected. Immunotherapy has the ability to target tumor cells specifically; however, little is known about the tumor microenvironment in DIPGs. We sought to characterize infiltrating immune cells and immunosuppressive factor expression in pediatric low- and high-grade gliomas and DIPG.

METHODS

Tumor microarrays were stained for infiltrating immune cells. RNA was isolated from snap-frozen tumor tissue and Nanostring analysis performed. DIPG and glioblastoma cells were co-cultured with healthy donor macrophages, T cells, or natural killer (NK) cells, and flow cytometry and cytotoxicity assays performed to characterize the phenotype and function, respectively, of the immune cells.

RESULTS

DIPG tumors do not have increased macrophage or T-cell infiltration relative to nontumor control, nor do they overexpress immunosuppressive factors such as programmed death ligand 1 and/or transforming growth factor β1. H3.3-K27M DIPG cells do not repolarize macrophages, but are not effectively targeted by activated allogeneic T cells. NK cells lysed all DIPG cultures.

CONCLUSIONS

DIPG tumors have neither a highly immunosuppressive nor inflammatory microenvironment. Therefore, major considerations for the development of immunotherapy will be the recruitment, activation, and retention of tumor-specific effector immune cells.

摘要

背景

弥漫性内在脑桥神经胶质瘤(DIPG)是一种每年在美国诊断出 300 名儿童的致命中枢神经系统肿瘤。放射治疗是唯一有效的治疗方法,可将总生存期延长至中位数 11 个月。由于其位于脑干,DIPG 无法进行手术切除。免疫疗法具有特异性靶向肿瘤细胞的能力;然而,对于 DIPG 中的肿瘤微环境知之甚少。我们试图描述小儿低级别和高级别神经胶质瘤和 DIPG 中浸润性免疫细胞和免疫抑制因子的表达。

方法

对肿瘤微阵列进行浸润性免疫细胞染色。从速冻肿瘤组织中分离 RNA,并进行 Nanostring 分析。将 DIPG 和胶质母细胞瘤细胞与健康供体巨噬细胞、T 细胞或自然杀伤(NK)细胞共培养,并进行流式细胞术和细胞毒性测定,分别表征免疫细胞的表型和功能。

结果

与非肿瘤对照相比,DIPG 肿瘤中巨噬细胞或 T 细胞浸润没有增加,也没有过度表达程序性死亡配体 1 和/或转化生长因子β1 等免疫抑制因子。H3.3-K27M DIPG 细胞不会使巨噬细胞重新极化,但不会被激活的同种异体 T 细胞有效靶向。NK 细胞溶解了所有 DIPG 培养物。

结论

DIPG 肿瘤既没有高度免疫抑制也没有炎症性微环境。因此,免疫疗法的主要考虑因素将是招募、激活和保留肿瘤特异性效应免疫细胞。

相似文献

3
Indolent course of brainstem tumors with K27M-H3.3 mutation.具有 K27M-H3.3 突变的脑干肿瘤惰性病程。
Pediatr Blood Cancer. 2020 Mar;67(3):e28102. doi: 10.1002/pbc.28102. Epub 2019 Dec 2.

引用本文的文献

本文引用的文献

5
Immunotherapy for brain tumors: understanding early successes and limitations.脑肿瘤的免疫疗法:了解早期的成功与局限。
Expert Rev Neurother. 2018 Mar;18(3):251-259. doi: 10.1080/14737175.2018.1425617. Epub 2018 Jan 11.
9
K27M-mutant histone-3 as a novel target for glioma immunotherapy.K27M突变型组蛋白-3作为神经胶质瘤免疫治疗的新靶点。
Oncoimmunology. 2017 May 12;6(7):e1328340. doi: 10.1080/2162402X.2017.1328340. eCollection 2017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验